Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 10/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21045452 | 1.00 | NPC1 (0.53) | NPC1RAB9ACNR1HTR1AFAAH | |
| SCHEMBL21045480 | 0.84 | CCNC (0.45) | CNR1FAAH | |
| SCHEMBL21045217 | 0.81 | LMNA (0.51) | NPC1RAB9ACNR1FAAH | |
| SCHEMBL21045167 | 0.80 | WNT1 (0.44) | — | |
| SCHEMBL29411489 | 0.80 | VNN1 (0.46) | — | |
| SCHEMBL21045172 | 0.80 | VNN1 (0.46) | — | |
| SCHEMBL21045197 | 0.80 | SMN1; SMN2 (0.41) | NPC1RAB9ACNR1 | |
| SCHEMBL21045501 | 0.79 | KDM4E (0.50) | — | |
| SCHEMBL21045388 | 0.79 | DYRK1A (0.40) | NPC1RAB9ACNR1FAAH | |
| SCHEMBL21045409 | 0.78 | CACNA1H (0.43) | CNR1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188035-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE LLC (US) | 2025-06-12 | — | — | US | disclosed |
| US-12247010-B2 | Tubulin inhibitors | LIN BIOSCIENCE INC. (TW) | 2025-03-11 | — | — | US | disclosed |
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089539-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | NPC1 421/4885RAB9A 959/4885CNR1 4572/4885 |
| US-12247010-B2 | Tubulin inhibitors | TUBB3, TUBB1, TUBB | NPC1 421/4885RAB9A 959/4885CNR1 4572/4885 |
| US-20250188035-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | NPC1 421/4885RAB9A 959/4885CNR1 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.